Lim Grace, Carvalho Brendan, George Ronald B, Bateman Brian T, Brummett Chad M, Ip Vivian H Y, Landau Ruth, Osmundson Sarah S, Raymond Britany, Richebe Philippe, Soens Mieke, Terplan Mishka
From the Department of Anesthesiology & Perioperative Medicine, University of Pittsburgh, Pittsburgh, Pennsylvania.
Department of Anesthesiology, Perioperative & Pain Medicine, Stanford University, Palo Alto, California.
Anesth Analg. 2024 Nov 6. doi: 10.1213/ANE.0000000000007237.
Pain management in pregnant and postpartum people with an opioid-use disorder (OUD) requires a balance between risks associated with opioid tolerance, including withdrawal or return to opioid use, considerations around social needs of the maternal-infant dyad, and the provision of adequate pain relief for the birth episode that is often characterized as the worst pain a person will experience in their lifetime. This multidisciplinary consensus statement between the Society for Obstetric Anesthesia and Perinatology (SOAP), Society for Maternal-Fetal Medicine (SMFM), and American Society of Regional Anesthesia and Pain Medicine (ASRA) provides a framework for pain management in obstetric patients with OUD. The purpose of this consensus statement is to provide practical and evidence-based recommendations and is targeted to health care providers in obstetrics and anesthesiology. The statement is focused on prenatal optimization of pain management, labor analgesia, and postvaginal delivery pain management, and postcesarean delivery pain management. Topics include a discussion of nonpharmacologic and pharmacologic options for pain management, medication management for OUD (eg, buprenorphine, methadone), considerations regarding urine drug testing, and other social aspects of care for maternal-infant dyads, as well as a review of current practices. The authors provide evidence-based recommendations to optimize pain management while reducing risks and complications associated with OUD in the peripartum period. Ultimately, this multidisciplinary consensus statement provides practical and concise clinical guidance to optimize pain management for people with OUD in the context of pregnancy to improve maternal and perinatal outcomes.
患有阿片类物质使用障碍(OUD)的孕妇和产后人群的疼痛管理需要在与阿片类物质耐受性相关的风险(包括戒断或恢复使用阿片类物质)、母婴二元组社会需求的考量以及为分娩过程提供充分的疼痛缓解之间取得平衡,分娩过程通常被认为是一个人一生中所经历的最剧烈的疼痛。产科麻醉与围产医学协会(SOAP)、母胎医学协会(SMFM)和美国区域麻醉与疼痛医学协会(ASRA)之间的这份多学科共识声明为患有OUD的产科患者的疼痛管理提供了一个框架。这份共识声明的目的是提供实用且基于证据的建议,目标受众是产科和麻醉学领域的医疗保健提供者。该声明聚焦于产前疼痛管理的优化、分娩镇痛、经阴道分娩后疼痛管理以及剖宫产术后疼痛管理。主题包括对疼痛管理的非药物和药物选择的讨论、OUD的药物管理(如丁丙诺啡、美沙酮)、尿液药物检测的考量以及母婴二元组护理的其他社会方面,以及对当前实践的回顾。作者提供基于证据的建议以优化疼痛管理,同时降低围产期与OUD相关的风险和并发症。最终,这份多学科共识声明提供了实用且简洁的临床指导,以在妊娠背景下优化患有OUD人群的疼痛管理,从而改善孕产妇和围产结局。